Corcept Therapeutics (CORT) Assets Average (2011 - 2026)

Corcept Therapeutics (CORT) has 16 years of Assets Average data on file, last reported at $825.8 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 2.1% year-over-year to $825.8 million; the trailing twelve-month figure through Mar 2026 stood at $825.8 million (down 2.1% YoY), and the FY2025 full-year result was $838.6 million, up 14.71% from the prior year.
• Assets Average eased to $825.8 million in Q1 2026, from $830.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $843.5 million in Q1 2025 to a low of $445.9 million in Q1 2022.
• A 5-year average of $668.4 million and a median of $638.7 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average fell 20.66% in 2022 and jumped 34.69% in 2023, its largest moves.
• Tracing CORT's Assets Average over 5 years: stood at $558.3 million in 2022, then advanced by 8.85% to $607.8 million in 2023, then surged by 33.67% to $812.4 million in 2024, then gained by 2.18% to $830.1 million in 2025, then decreased by 0.53% to $825.8 million in 2026.
• Business Quant data shows CORT's Assets Average at $825.8 million in Q1 2026, $830.1 million in Q4 2025, and $812.7 million in Q3 2025.